PSYCHOMOTOR SLOWING, NEGATIVE SYMPTOMS AND DOPAMINE-RECEPTOR AVAILABILITY - AN IBZM SPECT STUDY IN NEUROLEPTIC-TREATED AND DRUG-FREE SCHIZOPHRENIC-PATIENTS
A. Heinz et al., PSYCHOMOTOR SLOWING, NEGATIVE SYMPTOMS AND DOPAMINE-RECEPTOR AVAILABILITY - AN IBZM SPECT STUDY IN NEUROLEPTIC-TREATED AND DRUG-FREE SCHIZOPHRENIC-PATIENTS, Schizophrenia research, 31(1), 1998, pp. 19-26
Anhedonia and psychomotor slowing in schizophrenia have been attribute
d to a dysfunction of dopaminergic neurotransmission. To differentiate
between disease and drug-induced negative symptoms, we examined eight
drug-free and eight neuroleptic-treated schizophrenic patients. Posit
ive and negative symptoms and extrapyramidal side effects were assesse
d using standardized rating scales (PSAS, AMDP, SANS). 'Reaction time'
and 'motor speed' were measured using a computer-aided system and str
iatal dopamine D-2/D-3 receptor availability was assessed using [I-123
]IBZM SPECT. Psychomotor reaction time, parkinsonism, affective flatte
ning and avolition were increased in treated patients relative to the
untreated cohort and were negatively correlated with dopamine D-2/D-3
receptor availability. Significant positive correlations were found be
tween parkinsonism and affective flattening and between psychomotor sl
owing and avolition. Positive symptoms were not significantly associat
ed with striatal IBZM binding. These findings support the hypothesis t
hat neuroleptic-induced dopamine D-2/D-3 blockade in the striatum can
mimic certain negative symptoms, such as affective flattening and avol
ition, and indicates that psychomotor testing may be helpful in differ
entiating between disease and drug-induced negative symptoms. (C) 1998
Elsevier Science B.V. All rights reserved.